Institut National de la Santé et de la Recherche Médicale (Inserm) U1065, Université Côte d'Azur, Centre Méditerranéen de Médecine Moléculaire (C3M), Fédération Hospitalo-Universitaire (FHU) Oncoage, Nice, France.
Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
Cardiovasc Res. 2019 Jul 1;115(9):1393-1407. doi: 10.1093/cvr/cvz127.
Inflammation represents the driving feature of many diseases, including atherosclerosis, cancer, autoimmunity and infections. It is now established that metabolic processes shape a proper immune response and within this context the alteration in cellular cholesterol homeostasis has emerged as a culprit of many metabolic abnormalities observed in chronic inflammatory diseases. Cholesterol accumulation supports the inflammatory response of myeloid cells (i.e. augmentation of toll-like receptor signalling, inflammasome activation, and production of monocytes and neutrophils) which is beneficial in the response to infections, but worsens diseases associated with chronic metabolic inflammation including atherosclerosis. In addition to the innate immune system, cells of adaptive immunity, upon activation, have also been shown to undergo a reprogramming of cellular cholesterol metabolism, which results in the amplification of inflammatory responses. Aim of this review is to discuss (i) the molecular mechanisms linking cellular cholesterol metabolism to specific immune functions; (ii) how cellular cholesterol accumulation sustains chronic inflammatory diseases such as atherosclerosis; (iii) the immunometabolic profile of patients with defects of genes affecting cholesterol metabolism including familial hypercholesterolaemia, cholesteryl ester storage disease, Niemann-Pick type C, and immunoglobulin D syndrome/mevalonate kinase deficiency. Available data indicate that cholesterol immunometabolism plays a key role in directing immune cells function and set the stage for investigating the repurposing of existing 'metabolic' drugs to modulate the immune response.
炎症是许多疾病的主要特征,包括动脉粥样硬化、癌症、自身免疫和感染。现在已经确定,代谢过程塑造了适当的免疫反应,在这种情况下,细胞胆固醇稳态的改变已成为许多慢性炎症性疾病中观察到的许多代谢异常的罪魁祸首。胆固醇积累支持髓样细胞的炎症反应(即 Toll 样受体信号的增强、炎性小体的激活以及单核细胞和中性粒细胞的产生),这有利于对感染的反应,但会加重与慢性代谢炎症相关的疾病,包括动脉粥样硬化。除了先天免疫系统外,适应性免疫系统的细胞在激活后,其细胞胆固醇代谢也会发生重编程,导致炎症反应的放大。本综述的目的是讨论:(i)将细胞胆固醇代谢与特定免疫功能联系起来的分子机制;(ii)细胞胆固醇积累如何维持动脉粥样硬化等慢性炎症性疾病;(iii)影响胆固醇代谢的基因缺陷患者的免疫代谢特征,包括家族性高胆固醇血症、胆固醇酯贮积症、尼曼-匹克 C 型和免疫球蛋白 D 综合征/甲羟戊酸激酶缺乏症。现有数据表明,胆固醇免疫代谢在指导免疫细胞功能方面发挥着关键作用,并为研究重新利用现有的“代谢”药物来调节免疫反应奠定了基础。